Evofem Biosciences, Inc. · OTC:EVFM

Evofem Biosciences — Investor Presentation (January 2020)

20 slides from Evofem Biosciences's investor presentation, Jan 10, 2020

  1. Slide 1: Revolutionizing Women's Sexual and Reproductive Health

    Exhibit 99.1 Revolutionizing Women’s Sexual and Reproductive Health Saundra Pelletier, CEO January 2020 Nasdaq: EVFM 1 ©2020©2019 Evofem Biosciences, Inc.

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify forward looking statements by terms such as “may,” ”will,” “should,” “expect,

  3. Slide 3: About Evofem Biosciences

    About Evofem Biosciences A Clinical-Stage Biopharmaceutical Company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health First-in-Class Product Experienced Long-term Vision AMPHORA® Management 3 ©2020©2019 Evofem Biosciences

  4. Slide 4: Significant Value Drivers

    Significant Value Drivers Poised to disrupt the women’s healthcare market with an innovative, hormone-free, prescription contraceptive option – a $1B opportunity – May 25, 2020 PDUFA date (June 2020 launch anticipated*) Label expansion opportunity for prevention of STIs** – Primary indication: Chlam

  5. Slide 5: Significant Near-term Growth Opportunities

    Significant Near-term Growth Opportunities Anticipated Pregnancy U.S. Approval Prevention May 25, 2020 PDUFA Date NDA U.S. Amphora Launch Branded Launch Resubmission Launch Campaign Campaign Extension 2019 2020 2021 2022 Top-line Phase Initiate Anticipated 2b Results Pivotal Phase 3 Top-Line Phase 3

  6. Slide 6: The Amphora Opportunity

    The Amphora Opportunity Of the ~45M women at-risk for unintended pregnancy 17M segment out as potential Amphora adopters 8.9M • Self-identified as “beyond hormones” 28.0M 16.9M 8.0M • Seeking/open to alternatives to hormonal contraception Source: KJT Group Amphora Consumer Segmentation Market Resear

  7. Slide 7: The Amphora Woman: Target Segment Prioritization

    The Amphora Woman: Target Segment Prioritization Potential to Reach ~17M Women Priority Segment Reasons to Target Healthy Launch Heather [1.7M] Launch Type A Tara [3.7M] Self-identified as Curious “Beyond Hormones” Launch Connie [2.1M] Dutiful Launch Delilah [1.4M] Post- Apprehensive Launch Amy [4.5

  8. Slide 8: HCP Champions for Non-Hormonal Options

    HCP Champions for Non-Hormonal Options • Wants to empower women with reproductive freedom Segment #1 “Crusader Kelly” • Majority of patients are between the Female OB/GYN ages of 20-39 • High % of sexually active patients 17% 47% 19% • Highly motivated by new MOA/ z Segment #2 MVP-R™ “MVP Arianna” F

  9. Slide 9: HCPs Anticipate Significant Use of Amphora

    HCPs Anticipate Significant Use of Amphora Given the Need for Prescription Non-Hormonal Options Baseline Post-allocation % % Oral Contraceptives (Regular, 28-day) 30% 26% AMPHORA n/a 15% Hormonal IUD 12% 11% Condom 10% 8% When presented with Injectable 8% 7% the Amphora “target Oral Contraceptives (

  10. Slide 10: Preparing for Approval and Launch

    Preparing for Approval and Launch Sales Force Build-Out Establish a best-in-class sales organization in U.S. women’s health • Vice President of Sales • ~14 Regional Managers, 2 Area Sales Directors • ~125 Representatives • Targeting 100% coverage of top contraception prescribers Market Access Covera

  11. Slide 11: Broad Market Access Anticipated

    Broad Market Access Anticipated • ~80-90% of Amphora prescriptions will be covered at $0 copay through ACA Payer Assumptions • Amphora universally expected to be included on drug formularies based on (Based on 1:1 interviews with >30 payers) unique MOA • Anticipate a 12-pack box of Amphora to be pri

  12. Slide 12: Contraceptive Market Opportunity

    Contraceptive Market Opportunity Seeking a new hormone- free contraceptive1 ~17M Women ~885K Users2 ~5% Acquisition ~$1,200/woman ~7 Refills/Yr. acquired ~$175/ 12 applicators Box in each box ~$1 Billion Opportunity 1. Evofem Consumer Segmentation Project – Q1’2019. 2. Amphora Forecast Model Assumpt

  13. Slide 13: Amphora for the Prevention of Pregnancy

    Amphora for the Prevention of Pregnancy  First-in-Class MOA  Non-hormonal  Female-controlled  “On Demand” Multipurpose Vaginal pH Regulator (MVP-R™) 13 ©2020©2019 Evofem Biosciences, Inc.

  14. Slide 14: Amphora Attributes & Mechanism of Action

    Amphora Attributes & Mechanism of Action Body • Investigational, non-hormonal, acid- pH Level 5 buffering MVP-R vaginal gel candidate with bio-adhesive properties Water pH Level 7 • Designed to maintain a natural acidic Semen/Blood vaginal pH of 3.5 to 4.5 pH Level 7.1 - 8 – Inhibits motility of spe

  15. Slide 15: Significant Key Milestones Achieved

    Significant Key Milestones Achieved  Resubmitted Amphora NDA to FDA for prevention of pregnancy – First-in-class, hormone-free, female-controlled, on-demand contraceptive – May 25, 2020 PDUFA date – Accelerating pre-commercial activities in anticipation of June launch  Reported positive top-line r

  16. Slide 16: Amphora: Key Clinical Findings in Contraception

    Amphora: Key Clinical Findings in Contraception Efficacy Comparable to other on-demand methods AMPOWER Phase 3 Trial (86.3% typical use efficacy) • Single-arm, open-label trial Approaches hormonal contraception efficacy when used as directed (93.3%) • 112 U.S. sites • ~1,400 women, age 18-35 • >34,0

  17. Slide 17: Additional Exploratory Finding

    Additional Exploratory Finding… AMPOWER participants reported an almost three fold increase in sexual satisfaction 45.5% 16.9% 2.7x increase in sexual satisfaction Previous Amphora Birth Control 17 ©2020©2019 Evofem Biosciences, Inc.

  18. Slide 18: Opportunity to Impact Public Health

    Opportunity to Impact Public Health Expected AMPREVENCE Phase 2b 1.7M Annually1 Top-Line Results AddressableRegulatory Population Timeline 10 9.8% 8 50% 2021 2022 2022 Relative Risk Reduction 6 4.9% 4 78% 3.2% Relative Risk Reduction 2 Initiate Pivotal Potential 0.7% Phase 3 Trial U.S. Approval 0 Pl

  19. Slide 19: Our Time Is Now!

    OUR TIME IS NOW! There exists a significant unmet need in a market starved for innovation, and we have… An innovative, first-in-class product Compelling data The experience and the expertise And…we have the VISION 1919 ©2020©2019 Evofem Biosciences, Inc.

  20. Slide 20: ®

    ® 20 ©2020©2019 Evofem Biosciences, Inc.

Evofem Biosciences — Investor Presentation (January 2020) on 6ix